Pertinent to this study, suppression of REV1 is known to inhibit both cisplatin- and cyclophosphamide-induced mutagenesis, which sensitizes tumors to traditional therapeutics and suppresses the development of tumor chemoresistance [104]. The gene discussed is REV1; the disease is neoplasm.